1. The effect of probiotic Lactobacillus casei Shirota on knee osteoarthritis: a randomised double-blind, placebo-controlled clinical trial
- Author
-
Min Lei, Dawei Wang, Chunhua Zhang, Chunhua Guo, and Hua Lm
- Subjects
Male ,0301 basic medicine ,Microbiology (medical) ,Lactobacillus casei ,medicine.medical_specialty ,WOMAC ,Visual analogue scale ,Administration, Oral ,Osteoarthritis ,Placebo ,Severity of Illness Index ,Microbiology ,law.invention ,Placebos ,03 medical and health sciences ,Probiotic ,0302 clinical medicine ,Double-Blind Method ,law ,Internal medicine ,medicine ,Humans ,Adverse effect ,Aged ,030203 arthritis & rheumatology ,biology ,business.industry ,Probiotics ,Middle Aged ,Osteoarthritis, Knee ,medicine.disease ,biology.organism_classification ,Clinical trial ,Lacticaseibacillus casei ,C-Reactive Protein ,Treatment Outcome ,030104 developmental biology ,Physical therapy ,Female ,business - Abstract
Knee osteoarthritis (OA) treatment is challenging due to inefficacy and adverse effects of current medications. Probiotic treatment has been shown to promote bone metabolism, reduce pain and inflammatory responses of age-related musculoskeletal disorders, including OA. We aimed to investigate the effect of probiotic Lactobacillus casei Shirota (LcS) on patients with knee OA. 537 patients with knee OA were enrolled in this double-blind, placebo-controlled trial, who were randomised to receive skimmed milk containing either LcS or placebo daily for 6 months. Primary outcome was defined as changes in WOMAC (Western Ontario and McMaster Universities Osteoarthritis Index) and VAS (visual analog scale) scores. Secondary outcome was defined as changes in serum levels of high sensitivity C-reactive protein (hs-CRP). After 6 months of treatment, both WOMAC and VAS scores were significantly improved in the LcS groups of patients compared to the placebo group. Serum levels of hs-CRP were also significantly lower in patients receiving LcS than placebo. Strong linear correlations were observed between serum hs-CRP levels and WOMAC and VAS scores. LcS consumption could serve as a novel therapeutic option in the clinical management of knee OA, improving treatment outcome likely through reducing serum hs-CRP levels.
- Published
- 2017
- Full Text
- View/download PDF